Tagged with Germany

Germany Germany is one of Takeda’s largest markets, a major manufacturing base and an important clinical research location, yet its long-standing reputation for rapid access to innovation is coming under pressure. GM Germany Dr Ingeborg Borgheim discusses how Takeda is preparing its German operations for a new generation of launches, where…

Germany DACH should become a powerhouse for the Group Germany is emerging as a key growth and launch market for Ipsen, with the DACH region now ranking as the Group’s leading European affiliate and gaining momentum across Oncology, Rare Disease and Neuroscience. As Ipsen enters its next phase of growth, new…

Germany Our objective is to navigate ongoing healthcare reforms successfully, serve as a primary growth engine for Viatris in Europe, and maximize our contribution to patient care Simon von Boeselager, Country Manager Germany at Viatris brings extensive experience across pharmaceutical strategy, commercial leadership, and digital health. He highlights Germany’s role as…

Germany At its core, we need a reform of the welfare state. It’s indispensable, but it needs to be brought back to its core purpose: help for those who need it – not excessive transfer payments Klaus Holetschek served as Bavarian Health Minister during the pandemic and now chairs the CSU…

Germany My long-term hope is that dialysis will become much less common because we are able to diagnose and treat kidney disease earlier and more effectively Prof. Dr. Jörg Latus is passionate about the future of kidney care and the growing potential to prevent or slow disease progression. As Medical Director…

Germany We have the agility to move quickly, the expertise to navigate complex healthcare systems, and the commitment to bring innovative medicines to patients who are often overlooked Norgine is reshaping its DACH business around a new growth engine, pairing a well-established portfolio with an expanded push into rare and ultra-rare…

Germany We believe that flexibility, analytical drive, initiative, and a detailed, hands-on mindset are more important than industry experience Peter Gerckens, CEO at PharmaSGP combines a strong background in consulting, branding, and consumer healthcare with an entrepreneurial approach to pharmaceutical growth. He emphasizes data-driven decision-making, small, agile teams, and in-house capabilities…

Germany Tomas Mihal, General Manager for Germany at STADA, discusses the company’s diversified three-pillar model across consumer healthcare, generics and specialty medicines, highlighting its strong German market position, agile culture and five-year growth strategy. He outlines his priorities around acquisitions, digital and e-commerce expansion, selective biosimilar and innovation opportunities, supply resilience,…

Germany Growth in rare diseases is measured differently. It is not simply about launching new products, but about improving diagnosis, strengthening healthcare partnerships, and supporting patients throughout their journey. Those principles are shaping Orphalan’s next chapter, as the company expands beyond its longstanding focus on Wilson disease into new rare diseases.…

Germany Gerald Unden, General Manager DACH at Shionogi, believes that healthcare leadership begins with giving the patients of tomorrow a voice in the decisions made today. In this interview, he explains why antimicrobial resistance requires a long-term model of innovation, how Germany can help shape sustainable access to reserve antibiotics, and…

Germany Germany is the default first-choice European market for launching new, innovative medicines. But with the country’s pricing system under growing strain from both national and international pressures, some in the industry are asking how long that status can hold.   Germany is, by far, Europe’s leading country for fast and…

Germany Collaboration across institutions is not optional – it is necessary. The pace and complexity of the challenges demand it. As CEO of TUM University Hospital Munich, Dr med Martin Siess is trying to close a gap that has long dogged German medicine: strong basic research that rarely makes it to…